<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34485048</PMID><DateRevised><Year>2021</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2213-0071</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Respiratory medicine case reports</Title><ISOAbbreviation>Respir Med Case Rep</ISOAbbreviation></Journal><ArticleTitle>Treatment of a COVID-19 long hauler with an amniotic fluid-derived extracellular vesicle biologic.</ArticleTitle><Pagination><StartPage>101502</StartPage><MedlinePgn>101502</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101502</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rmcr.2021.101502</ELocationID><Abstract><AbstractText>Post-COVID-19 infection symptoms such as mental fog, tachycardia, and extreme fatigue are just a few of the symptoms wreaking havoc on patients' lives. Patients with long-term symptoms following COVID-19 are being called long haulers. To date, long haulers are receiving little to no guidance from physicians on their lingering COVID-19 symptoms with limited treatment options available. Zofin is an acellular biologic that contains the extracellular vesicle (EV) fraction of human amniotic fluid and is under investigation for use as a COVID-19 therapeutic. We obtained FDA and IRB approval to investigate the therapeutic use of Zofin in a single long hauler patient case experiencing prolonged shortness of breath and respiratory impairment. Administration of the EV product was shown to be safe. Furthermore, demonstrated respiratory improvements through chest X ray images and oxygen saturation measurement. The single patient IND studies were completed without any reported adverse events or safety concerns. Furthermore, these completed studies demonstrate the feasibility and a therapeutic potential of amniotic fluid-derived EVs for COVID-19 long hauler intervention.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mitrani</LastName><ForeName>Maria Ines</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Organicell Regenerative Medicine, Inc., Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellio</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Organicell Regenerative Medicine, Inc., Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meglin</LastName><ForeName>Allen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Advanced Regenerative Therapies, Savanah, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Aisha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>AssureImmune LLC., Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Xiumin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>AssureImmune LLC., Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haskell</LastName><ForeName>Gwendolyn</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Organicell Regenerative Medicine, Inc., Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arango</LastName><ForeName>Alissa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Organicell Regenerative Medicine, Inc., Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shapiro</LastName><ForeName>George C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Organicell Regenerative Medicine, Inc., Miami, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Respir Med Case Rep</MedlineTA><NlmUniqueID>101604463</NlmUniqueID><ISSNLinking>2213-0071</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Extracellular vesicles</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Long-hauler</Keyword><Keyword MajorTopicYN="N">Perinatal</Keyword></KeywordList><CoiStatement>MM and GS report personal fees and equity from Organicell Regenerative Medicine, Inc., outside the submitted work. In addition, MM has a patent COMPOSITIONS COMPRISING NANOPARTICLES, METHOD OF MAKING AND USES THEREOF pending. MB, GH, and AA report personal fees from Organicell Regenerative Medicine, Inc., outside the submitted work. AM is a medical advisor to Organicell Regenerative Medicine. AK and XX discloses a relationship with AssureImmune Cord Blood Bank that includes equity.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34485048</ArticleId><ArticleId IdType="pmc">PMC8405236</ArticleId><ArticleId IdType="doi">10.1016/j.rmcr.2021.101502</ArticleId><ArticleId IdType="pii">S2213-0071(21)00164-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baig A.M. Deleterious outcomes in long-hauler COVID-19: the effects of SARS-CoV-2 on the CNS in chronic COVID syndrome. ACS Chem. Neurosci. 2020;11(24):4017&#x2013;4020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33275404</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin R. JAMA; 2020. As Their Numbers Grow, COVID-19 "Long Haulers" Stump Experts.</Citation><ArticleIdList><ArticleId IdType="pubmed">32965460</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard F., Perego E. How and why patients made Long Covid. Soc. Sci. Med. 2021;268:113426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury M. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur. Respir. J. 2020;55(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7144273</ArticleId><ArticleId IdType="pubmed">32265310</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitrani M.I. Case report: administration of amniotic fluid-derived nanoparticles in three severely Ill COVID-19 patients. Front. Med. 2021;8(242)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8010176</ArticleId><ArticleId IdType="pubmed">33816515</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobi A. Portable chest X-ray in coronavirus disease-19 (COVID-19): a pictorial review. Clin. Imag. 2020;64:35&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7141645</ArticleId><ArticleId IdType="pubmed">32302927</ArticleId></ArticleIdList></Reference><Reference><Citation>Barile L. Roles of exosomes in cardioprotection. Eur. Heart J. 2017;38(18):1372&#x2013;1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">27443883</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams A.M. Early single-dose treatment with exosomes provides neuroprotection and improves blood-brain bar-rier integrity in swine model of traumatic brain injury and hemorrhagic shock. J Trauma Acute Care Surg. 2020;88(2):207&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">31804413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha D.H. Mesenchymal stem/stromal cell-derived exosomes for immunomodulatory therapeutics and skin regen-eration. Cells. 2020;9(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7290908</ArticleId><ArticleId IdType="pubmed">32392899</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu A. Therapeutic potential of mesenchymal stem/stromal cell-derived secretome and vesicles for lung injury and disease. Expet Opin. Biol. Ther. 2020;20(2):125&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6981051</ArticleId><ArticleId IdType="pubmed">31701782</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah T.G., Predescu D., Predescu S. Mesenchymal stem cells-derived extracellular vesicles in acute respiratory distress syndrome: a review of current literature and potential future treatment options. Clin. Transl. Med. 2019;8(1):25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6739436</ArticleId><ArticleId IdType="pubmed">31512000</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchiya A. Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases. Inflamm. Regen. 2020;40:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7306412</ArticleId><ArticleId IdType="pubmed">32582401</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>